An international phase 3 clinical trial found that a new targeted treatment, given in combination with a standard chemotherapy, extended survival for select patients with advanced gastric or gastroesophageal junction cancer.
Anti-Mullerian hormone, traditionally thought of as a passive byproduct of polycystic ovary syndrome, may actually play an active role in the disorder, according to new research.
As part of a new cross-college initiative designed to accelerate engineering innovations in medicine, Cornell Engineering is piloting an M.D.-M.Eng. program that allows medical students at Weill Cornell Medicine to earn a one-year professional Master of Engineering degree.
Researchers at Weill Cornell Medicine and Cornell’s Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.
Nine students and recent graduates representing Cornell’s four contract colleges were selected to receive the 2024 State University of New York Chancellor’s Award for Student Excellence.
Following a sweeping effort in 2019 to address clinical care team well-being across Weill Cornell Medicine, physicians note a reduction in stress and feelings of burnout compared to previous surveys, according to a new report from the institution.
An alternative statistical method honed and advanced by Cornell researchers can make clinical trials more reliable and trustworthy while also helping to remedy what has been called a “replicability crisis” in the scientific community.
Cornell Tech researchers have developed a mixed-reality driving simulator system that could lower the cost of testing vehicle systems and interfaces, such as the turn signal and dashboard.
Obesity may spur DNA damage in the breast tissue of women who carry BRCA1 or BRCA2 mutations, possibly contributing to breast cancer development in this already high-risk group, according to new multi-institutional translational research led by Weill Cornell Medicine scientists.